ABSTRACT. In Krabbe's disease (globoid cell leukodystrophy), galactosylsphingosine (psychosine) is considered to be a causative agent of the pathology found in the nervous system of the patients. In our study, we examined the cytotoxic effect of psychosine in neural cell cultures derived from the rat nervous system. The concentration of toxic thresholds varied from cell type to cell type. The 50% of toxic doses for oligodendrocytes, astrocytes, and the sensory neurons of the dorsal root ganglia were 8, 20, and 30 JLg/mL, respectively. Oligodendrocytes, therefore, appeared to show a higher sensitivity to psychosine than did astrocytes or neurons. When phorbol ester or DMSO was applied simultaneously with psychosine as protective agents in enriched cultures of rat oligodendrocytes, the total number of live cells and galactocerebroside-positive cells and the 2'3'-cyclic nucleotide 3'-phosphohydrolase activity in these cultures were considerably higher as compared with their levels in the experimental cultures treated with psychosine alone. These results indicate that phorbol ester and DMSO could serve as protective agents for psychosine neurotoxicity. (Pediatr Res 28: 473-476, 1990) Abbreviations GLD, globoid cell leukodystrophy EMEM, Eagle's minimum essential medium PDB, 4-iJ-phorbol-12, 13-dibutyrate OL, oligodendrocyte CNP, 2'3'-cyclic nucleotide 3'-phosphohydrolase GC, galactocerebroside GF AP, glial fibrillary acidic protein NF, neurofilament TD so , 50% toxic dose Krabbe's disease (OLD) is an inherited neurologic disorder in children caused by galactosylceramide-d-galactosidase deficiency (l ). In OLD, unlike in other sphingolipid storage diseases, galactosylceramide, the natural substrate of the deficient enzyme, does not accumulate in the CNS, and the overall concentration in the brain is much lower than normal (2), An abnormal accumulation in the brains of OLD patients of galactosylsphingosine (psychosine), which is also a substrate for the missing enzyme, was demonstrated by Svennerholm et at. (3), These authors confirmed the "psychosine hypothesis" proposed by Miyatake and Suzuki (4) that psychosine is highly cytotoxic and responsible for the extensive pathology of the disease (5), Received December 18, 1989: accepted June 28, 1990. Correspondence: Seung U. Kim, MD., PhD., Division of Neurology, University Hospital. University of British Columbia, Vancouver, B.c., V6T IW5, Canada.
Previous studies have reported that psychosine is cytotoxic in the cell culture system (4) and in vivo when it is injected intracerebrally (6) . In OLD, the affected organ is almost exclusively the nervous system, which shows dysmyelination of the CNS and the peripheral nerve. To facilitate our understanding of how psychosine elicits dysmyelination of the CNS, we examined its cytotoxic effect on the neural cell cultures derived from newborn rat brain and dorsal root ganglion. In addition, attempts were made to neutralize psychosine cytotoxicity in rat brain cultures by supplementing two reagents, DMSO and phorbol ester PDB, as protective agents. These reagents showed a considerable degree of protective effect on psychosine toxicity in rat neural cell cultures.
MATERIALS AND METHODS
Cell culture. Dissociated cell cultures of newborn (2-5 d) rat brain were prepared according to the method previously described (7, 8) . Dispersed cells were plated onto 9-mm Aclar (Allied Chemical Corp., New York, NY) coverslips (5 X 10 4 cells/coverslip) previously coated with poly-L-Iysine (10 JLg/mL) that were housed in 35-mm plastic dishes, The nutrient medium was composed of EMEM containing 5% FCS, 5 mg/rnl, Dglucose, and 25 JLg/mL gentamicin. Dorsal root ganglia were excised from newborn rats, dissociated into single cells by trypsinization as above, and plated onto the coverslips, The nutrient medium was made of 10% FCS, 100 ng/ml, nerve growth factor, 5 mg/rnl, D-glucose, and 25 JLg/mL gentamicin in EMEM.
OL of 4-wk-old rats were prepared from the whole brain using the procedure previously described for human OL (9), In brief, the brains were cut into cubes of approximately 3 x 3 x 3 mm and incubated in calcium and magnesium-free Hanks' balanced salt solution containing 0.25% trypsin and 20 JLg/mL DNAse for 45 min at 3rc. Dissociated cells were passed through a nylon filter of 100-JLm pore size, and the filtrate was then centrifuged in 30% Percoll (Pharmacia, Piscataway, NJ) for 30 min at 15 000 rpm. The OL layer was collected, washed, and resuspended in a nutrient medium of EMEM containing 5% FCS, 5 mg/rnl. Dglucose, and 25 JLg/mL gentamicin. Collected OL were seeded onto 9-mm Aclar coverslips and in 24 multiwell plates that had been previously coated with poly-t.-lysine. All cell cultures were incubated at 370C in a humidified atmosphere of 5% CO2, Psychosine, DMSO, and PDB treatment. Psychosine (Sigma Chemical Co., St. Louis, MO) was directly dissolved in the nutrient medium by sonication for 5 min at the concentration of 0.5 mg/rnl, and then sterilized by filtering through a 0.2-JLm membrane filter. This solution was further diluted to desired concentrations by the nutrient medium. Three to 5 d after the preparation, cultures were treated with the various concentrations of psychosine.
To determine whether PDB and DMSO protect psychosine 474 SUGAMA ET AL. 
RESULTS
toxicity, OL cultures were simultaneo usly incubated with IO Jlg/ mL psychosine and 10 nM POB or 0.5% OMSO. CeIl survival, immunohistochemistry, and CNP enzyme assays were performed in these cultures. Preliminary experiments were conducted to ascertain that 10 nM POB and 0.5% OMSO at concentration were not toxic to the cultures (data not shown). AlI determinations were carried out 3 d after the onset of the treatm ent. Determination ofcell survival. Th ree d after the treatm ent , ceIl survival was evaluated by the trypan blue exclusion test (10) .
Enzyme assay. Activity of CNP was carried out by a modification of the method of Sims and Carnegie (11), with adenosine 2',3'-cyclic mono phosphate as a substrate. Cells grown in 24 multiwelI plates were harvested by scraping and then were pelleted by low-speed centrifugation. T he pelIets were washed twice in PBS and resuspended with 2% T riton-X imidazole buffer. T he spec act of CNP was expressed as nmol substrate converted to product per min of incub ation at 3rC per welI in the hom ogenate. Protein content was determined by the BioRad assay (BioRad Laboratories, Richmond, CA) using BSA as standard.
Im m unohistochem istry. Immun olabeling of cultured celIs grown on 9-mm coverslips was performed using mouse anti-GC MAb (a ceIl type-specific marker for OL) (9), rabbit anti-GFAP antibody (a cell type-specific marker for astrocytes) (12) , and rat anti-N F 150-kOa triplet protein MAb (a ceIl type-specific marker for neurons) (13) as described previously (14) . Coverslips were incubated with mouse anti-GC MAb (1:2) for 30 min at room tem perature. Th is was folIowed by goat antimouse IgG conjugated to fluorescein ( I:40 dilution) for another 30 min. Coverslips were then fixed in cold acid-alcohol (95% ethan ol, 5% acetic acid) at -20°C for 15 min. After rehydration with PBS, they were mounted on slides in glycerol-PBS. Cultures were fixed in acid-alcohol as above and then incubated in monoclonal (rat) anti-NF ant ibody (1:2) or rabbit anti-GFAP antibo dy (1:50) overnight at 4°C. Coverslips were washed in PBS and then incub ated with fluorescein conjugated with goat ant irat or antirabbit IgG (1:40). Immunostained cells were viewed and counted und er a Zeiss Universal fluorescence microscope equipped with phase-cont rast and fluorescence optics.
Hybridom a ceIl lines that produ ce MAb specific for GC (15) and NF (13) were grown in the laboratory (S.U.K.), and culture supernatants were used in imm unostaining. Rabbit antibody specific for GFAP was purchased from OAKO (Carpi nteria, CA), and fluorescein-conjugated second antibodies were obtained from Cappel (Westchester, PA).
Psychosine tox icity. Observations of living cells under phase contrast microscopy 3 d after psychosine treatment showed that the toxic effects of psychosine depended on the concentration of psychosine in the medium . In general, at the lower concentrations, there was an increased perinuclear granu larity, formation of intracytoplasmic vacuolation, and inhibited outgrowth of neurites and processes. At the higher concentrations, the celIs tended to float off from the coverslips, showing shrinkage of the ceIl bodies and phase-dark ceIl bodies indicating ceIl death .
To determ ine the effect of the various psychosine concentration s, we used fluorescence microscopic examinati on to count the total nu mbers of GC-positive celIs (OL), GFAP-positive celIs (astrocytes), and Nf -positive celIs (neuro ns). Of these, we recorded the number of (and thu s the percentage of) OL with norm al surface stai n, astrocytes with preserved norm al configuration and stain, and neurons with processes greater than three cell diamet ers (Fig. I) . In newborn rat brain cultures, the number of GC-positive OL began to decrease at a psychosine concent ration of 2-4 Jl gf mL (TOso -8 Jlg/mL), whereas the number of GFAP-positive celIs (astrocytes) only started to decrease at a psychosine concentra tion of 8 Jlg/ mL (TO so -20 Jlg/mL); the (Fig. 2) .
Sister cultures of rat brain were treated with the various concentrations of psychosine, an d the activity of CNP was measured . As shown in Figure 3 , CNP activity started to decrease at th e concentration of 2 Jlg/mL psychosine. When GC-positive cells were examined und er the fluorescence microscope (Fig. 2) , th e number ofOL dropped to 50% at a psychosine concentration of 4 Jlg/m L and to nearly zero at a psychosine conce ntra tion of 16 JLg/ mL. Although GC immunoreactive cells dropped to the 50% level, the CNP activity (Fig. 3) decreased only 25% at 4 Jlg/ ...
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The cytotoxicity of psychosine is now well known, and the extensive pathology found in Krabbe's disease could be attrib uted to the toxic effects of accumulated psychosine in the affected tissues. When psychosine was injected into rat brain , necrosis an d hem orrh age occurred and the white matte r of the ani ma ls was found to be edema tous with num erous degenerating myelin and axons (6) . When more than 0.1 mM of psychosine was applied to cultured rat cerebellar explants, whole explants degenerated completely (4). In tissue, only OL synthesized any substantial amo unt of cerebroside and psychosine. Thus, the deficiency in ,B-galactosidase enzyme in GLD and twitcher mutant, leading to accumu latio n of psychosine, would only be app arent in OL and would show little toxic activity towa rd non-OL such as astrocytes or neurons. In our study, psychosine was found to be more toxic to OL than to astrocytes or neur ons as demonstrated. Neverth eless, psychosine cytotoxicity was also evident in astrocytes and neu rons.
As shown in Figure 2 , the number of GC-positive OL drops to 50% at a psychosine concentration of 4 JLg/ mL and to nearly zero at 16 Jlg/rnL. When CN P activity was assayed (Fig. 3) , th e mL psychosine, and the CNP activity was 50% of the cont rol when GC-posi tive cells were nearly zero at a psychosine conce ntration of 16 JLg/m L. T his discrepancy might be explained by the loss of GC immunostaining on the OL cell surface while retain ing enzyme activity of CNP after the exposure to psychosine.
Protective effects of PDB and DMS O. Because OL had the greater sensitivity to psychosine, we focussed on the effects of prote ctive reagents on OL. Using the Percoll density gradient method described above, we obtained OL-rich cultu res with 80-95% purity as determined by immunostaining with mouse antiGCMAb.
In rat OL cultures treated with psychosine alone for 3 d, there were few live cells under the phase contrast microscopy and GCpositive cells after the immunostaining. When the cultures were supplemented with PDB or DMSO , there were a considerable number of well-preserved live cells and also norm al-app earing GC-imm unoreactive OL (Figs. 4A and Band 5). The CNP activity in the cultures exposed to psychosine supplemen ted with PDB or DMSO was approxi mately 50% of the normal contro ls, but this activity was mo re than 2-fold that of the cultures exposed to psychosine alone (approxima tely 20% of the normal cont rol) (Fig. 5) . activity dropp ed to 25% at 4 ug/ml. and to 50% at 16 /lg/m L. T his discrepancy in the results may come from the difference in the sensitivity of detection systems used. Fluorescence microscopy of GC imm unostaining of cultured OL involves incubation of live cells in antibody solutions for about I h. During this procedure, damaged cells are prone to detach from the coversIips, resulting in lower numbers tha n expected. For this reason, data obtained by CNP biochemical assay are often more reliable than results of immunostaining.
The severity of psychosine toxicity was dose dependent, but the TD 50 of psychosine varied from one cell type to another. The question is where these differences come from. In a previous study of twitcher mouse (16) , the concentration of psychosine was found to be several tim es higher in the nervous tissue (cerebrum, 63 ng/rng protein; spinal cord, 3 12 ng/rng protein ) than in the somatic organs (liver, 0.4 ng/mg prote in; kidney, 10 ng/mg protein). The concentration of psychosine in somatic organs and the brain of infantile GLD (17) and twitcher mouse ( 16) correlates well with pathol ogic changes. Because psychosine is a Iysosphingolipid of GC, these two are chemically very close. T herefore, psychosine might accumulate in the myelin sheath in place of GC, a major component of myelin, and lead to the demise of OL, the cells that are responsible for synthesis and maintenance of central myelin. T he reason these cell types are not involved in the pathogenesis of GLD and the twitcher mutant mouse might be that neurons and astrocytes do not contain any noticeable amo unt of GC or psychosine. Although the mechanism of psychosine toxicity has not been clarified, recent studies have shown several interesting findings concerning psychosine biochemistry. Psychosine has been demon strated to inhibit phosphorylation (18) , cytochrome oxidase C (19) , and protein kinase C activity (20) . All these inhibitory activities of psychosine may also contribute to the neurotoxic effects attributed to psychosine in tissues.
The protective effects of phorbol ester and DMSO on psychosine toxicity were examined in culture models, and the results indicate that phorbol ester and DMSO were effective in attenuating psychosine neurotoxicity. Phorbol ester has a variety of effects on the nervous system. T he effects of phorbol ester are mediated by a specific cell membrane receptor, which is now known to be the enzyme protein kinase C, that is particularly abundant in the nervous system (2 I-23). Psychosine inhibits protein kinase C activity, and at a higher concentration it becomes cytotoxic (20) . We expected that phorbol ester would negate the inhibition of protein kinase C by psychosine because phorbol ester is one of the most effective protein kinase C activators. We therefore attempted to apply phorbol ester as a protective agent for psychosine toxicity. Another reagent, DMSO, also is known to possess many stimulatory functions for a variety of cells (24) . A recent study has shown that activities of several lysosomal enzymes, includin g {3-galactosidase, were stimulated in DMSO-treated fibroblast cultures (25) . We predicted that applying DMSO together with psychosine would enhance the degradation of psychosine and thus result in reduction in psychosine toxicity. Both of the reagents, phorbol ester and DMSO, apparently protected cultured OL to a certain degree from psychosine toxicity.
Recently, a number of procedures for the treatment of lysosomal storage diseases, such as enzyme replacement therap y (bone marrow transplantation , lysosomal therapy, and gene transfer), have been explored, but none of these have been successful in preventin g or treatin g brain damage. Because DMSO has been used in a variety of clinical settings (24) , effectiveness of this reagent and also others such as phorbol esters or protein kinase C activators might form the first step for a chemotherapeutic approach for GLD patient s.
